Researchers identify potential therapeutic target in aggressive breast cancer cells

November 15, 2017, Rapamycin Press
Micrograph showing a lymph node invaded by ductal breast carcinoma, with extension of the tumour beyond the lymph node. Credit: Nephron/Wikipedia

An especially aggressive breast cancer cell can respond to hormone therapy if they express a specific protein known as estrogen receptor beta (ERβ), according to new research published on the cover of Oncotarget. The findings also revealed additional molecules that the researchers suggest targeting to develop drugs for this breast cancer type.

Breast contain several types of hormone receptors for estrogen and/or progesterone that contribute to the growth and function of breast cells. Triple negative (TNBC), which occurs in 15 percent of diagnosed breast cancers, is an aggressive cancer type defined by the absence of specific receptor proteins that bind the hormones estrogen and progesterone that are present on normal breast cells. The absence of these receptors makes these cancers resistant to targeted hormone treatment, which is commonly used in other breast cancers.

Despite advances in treatment methods, patients with TNBC have a poor prognosis because the cancer is more likely to spread to other organs. In the study, researchers at the Mayo Clinic in Minnesota aimed to better understand and characterize the molecular signaling pathways in these cells in order to identify better treatments.

The researchers found that the growth of TNB cells that lacked alpha (ER?) in the lab could be significantly slowed by treatment with estrogen or estrogen-like chemicals if the cells presented a second estrogen receptor, ERβ. They also tested this approach in a mouse model which had TNB cells grafted to it, and found that estrogen could prevent tumor growth and in some cases even cause tumor regression, if the cells expressed ERβ.

Oncotarget | Interview with Dr. John R. Hawse from the Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA talking about their paper "ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer". Credit: Oncotarget

Importantly, further analysis found that the effects of estrogen on ERβ were in part due to proteins called cyclin-dependent kinases (CDKs) that control when and how cells divide.

"Our data suggests that the tumor-suppressive effects of ERβ in triple negative breast cancer are partly controlled by cell cycle regulating proteins suggesting that targeting these proteins may lead to potentially new and effective therapies for triple negative cancer," said Dr. Hawse

The researchers also note that other studies have observed that patients with TNBC who lack ERα but have ERβ have not only an increased survival rate but are also more likely to become cancer free, supporting the notion that drugs designed specifically to activate ERβ, such as estrogen, may provide therapeutic benefits in these patients.

These preliminary findings will have to be evaluated further in cellular and animal models before they can be considered for a clinical trial, a task that the research team is expected to take on in future studies.

Explore further: Researchers identify novel treatment for aggressive form of breast cancer

More information: Jordan M. Reese et al, ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer, Oncotarget (2017). DOI: 10.18632/oncotarget.21787

Related Stories

Researchers identify novel treatment for aggressive form of breast cancer

May 23, 2016
A recent study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine revealed that triple-negative breast cancer (TNBC), which has generally been unresponsive to hormone ...

Genetic targets to chemo-resistant breast cancer identified

October 3, 2017
Research led by Dr. Carlos Arteaga, Director of the Harold C. Simmons Comprehensive Cancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast cancer.

First-in-class drug holds promise for therapy-resistant breast cancer

August 8, 2017
UT Southwestern Simmons Cancer Center researchers have shown that a first-in-class molecule can prevent breast cancer growth when traditional therapies stop working.

New insights into mechanisms of breast cancer development and resistance to therapy

January 9, 2017
Why does breast cancer develop and how come certain patients are resistant to established therapies? Researchers from the University of Basel have gained new insights into the molecular processes in breast tissue. They identified ...

Exposure to BPA substitute, BPS, multiplies breast cancer cells

April 2, 2017
Bisphenol S (BPS), a substitute for the chemical bisphenol A (BPA) in the plastic industry, shows the potential for increasing the aggressiveness of breast cancer through its behavior as an endocrine-disrupting chemical, ...

A key to unlocking the mystery of triple negative breast cancer

October 24, 2016
A study conducted at the Research Institute of the McGill University Health Centre (RI-MUHC) suggests screening breast cancer patients for the prolactin receptor could improve the prognosis for patient and may help them avoid ...

Recommended for you

DNA vaccine leads to immune responses in HPV-related head and neck cancer

September 21, 2018
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.